Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Security and Efficacy of Triple Therapy Including Direct-Acting Antivirals Against Chronic Hepatitis C Infection In HIV-Coinfected Patients In Real-Life Conditions: The Prospective HEPAVIR Cohort.

Next Previous
Trial Profile

Security and Efficacy of Triple Therapy Including Direct-Acting Antivirals Against Chronic Hepatitis C Infection In HIV-Coinfected Patients In Real-Life Conditions: The Prospective HEPAVIR Cohort.

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Boceprevir (Primary) ; Daclatasvir (Primary) ; Dasabuvir (Primary) ; Elbasvir (Primary) ; Elbasvir/grazoprevir (Primary) ; Grazoprevir (Primary) ; Ledipasvir (Primary) ; Ombitasvir (Primary) ; Paritaprevir (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary) ; Telaprevir (Primary) ; Velpatasvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HEPAVIR-DAA

Most Recent Events

  • 11 Jun 2022 Results (N=644) assessing high efficacy of Glecaprevir/Pibrentasvir for HCV-Infected individuals with active drug use from two studies (NCT02057003 and NCT02333292) published in the Journal of Infection
  • 30 Oct 2021 Results assessing fficacy and tolerability of G/P in HIV/HCV- coinfected patients in HEPAVIR- DAA cohort and GEHEP- MONO cohort studies were presented at the 18th European AIDS Conference.
  • 07 Aug 2020 Results (n=1035) assessing impact of HIV infection on the risk of developing hepatocellular carcinoma (HCC) in HCV-infected patients who achieve sustained virological response (SVR) with direct-acting antiviral in two studies (HEPAVIR-DAA;NCT0205700 & GEHEP-MONO;NCT02333292) published in the Clinical Infectious Diseases.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top